Skip to main content
Sign In
 

Women's Cancer Developmental Therapeutics Program


​The Women's Cancer Developmental Therapuetic Program (WCTD) seeks to increase the development of novel cancer therapies in Gynecologic and Breast cancers, leading to a decrease in cancer-related morbidity and mortality for patients. Additionally, the WCTD seeks to increase access to Phase I/II clinical trials of novel cancer therapies for patients with Gynecologic and Breast cancers.

Women's Cancers include: 

Breast, Endometrial, Ovarian, Fallopian tube, Peritoneal, Cervical, Vulvar and Vaginal. 

  • It is estimated that there will be about 252,710 new cases of breast cancer and 274,040 gynecologic cancer diagnosed and approximately 40,610 deaths from breast cancer and 63,200 deaths from gynecologic cancers in the United States during 2017 (American Cancer Society. Cancer Facts & Figures 2017). 
  • Only about 5% of women with a gynecologic cancer participate in the dozens of clinical trials in gynecologic cancers. (foundationsforwomenscancer).
  • According to Cancer Therapy Evaluation Program within NCI, approximately 3% of adult cancer patients participate in clinical trials. 

Clinical trials are a crucial step in finding new and improved ways to improve treatment for women diagnosed with cancer

Mission: 

To increase the development of novel cancer therapies in Gynecologic and Breast cancers, leading to a decrease in cancer-related morbidity and mortality for patients. Increase access to Phase I/II clinical trials of novel cancer therapies for patients with Gynecologic and Breast cancers.